Predictive Oncology has joined the race to develop a Covid-19 vaccine with the acquisition of Soluble Therapeutics, followed by collaboration and licensing of a new nanoparticle vaccine technology platform.
The vaccine technology, based on a self-assembling nanoparticle called NSP1, has surface properties enabling the rapid design and display of viral receptor stems for virtually all viruses.
In previous studies, vaccines with NSP10-based Nanoparticles generated significantly high titers against a herpes viral protein called glycoprotein D in rabbits.
The high levels of titers were observed with a simple injection and a second booster, without adjuvants or transfection agents.